Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
TScan Therapeutics, Inc. - Common Stock
(NQ:
TCRX
)
1.075
+0.025 (+2.38%)
Streaming Delayed Price
Updated: 2:20 PM EDT, Jul 7, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about TScan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
TScan Therapeutics Appoints Commercial Leader Stephen Camiolo as Senior Vice President, Market Access
March 27, 2025
Mr. Camiolo brings to TScan demonstrated commercial readiness and cell therapy launch experience
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Breaking Down TScan Therapeutics: 4 Analysts Share Their Views
↗
March 06, 2025
Via
Benzinga
TScan Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
March 05, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the TD Cowen 45th Annual Health Care Conference
February 27, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
The Analyst Landscape: 5 Takes On TScan Therapeutics
↗
December 11, 2024
Via
Benzinga
Demystifying TScan Therapeutics: Insights From 4 Analyst Reviews
↗
November 06, 2024
Via
Benzinga
TScan Therapeutics to Participate in the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
February 18, 2025
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
December 26, 2024
Via
Benzinga
Why Is TScan Therapeutics Stock Gaining Today?
↗
December 26, 2024
TScan Therapeutics' stock rises after announcing a $30 million financing deal with Lynx1, extending its cash runway into 2027.
Via
Benzinga
TScan Therapeutics Announces $30 Million Registered Direct Offering at a 37% Premium
December 26, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Expert Outlook: TScan Therapeutics Through The Eyes Of 5 Analysts
↗
August 13, 2024
Via
Benzinga
The Analyst Landscape: 7 Takes On TScan Therapeutics
↗
June 04, 2024
Via
Benzinga
TScan Therapeutics Refinances Existing Convertible Debt Facility with Term Loan for up to $52.5 Million from Silicon Valley Bank
December 23, 2024
New non-dilutive structure replaces existing convertible facility maturing in 2026, and extends loan maturity to 2029
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Present Updated Data from the Ongoing ALLOHA™ Phase 1 Heme Trial During Oral Session at the 66th American Society of Hematology Annual Meeting and Exposition
December 09, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Named a Top Place to Work by The Boston Globe for Three Consecutive Years
December 05, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
Key Takeaways From TScan Therapeutics Analyst Ratings
↗
May 13, 2024
Via
Benzinga
TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Heme Development Strategy
December 02, 2024
Company to also provide an update on PLEXI-T™ Phase 1 solid tumor trial
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Oral Presentation of Data from the ALLOHA™ Phase 1 Heme Trial at the 66th American Society of Hematology Annual Meeting and Exposition
November 05, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer 39th Annual Meeting
October 04, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics to Participate in Upcoming Investor Conferences
August 29, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Meets EPS, Misses Revenue for Q2 2024
↗
August 12, 2024
TCRX stock results show that TScan Therapeutics met analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via
InvestorPlace
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
August 12, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Updates to its Board of Directors
June 14, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentation at the Jefferies Global Healthcare Conference
May 30, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Receives FDA’s Regenerative Medicine Advanced Therapy (RMAT) Designation for its Two Lead TCR-T Therapy Candidates for the Treatment of Heme Malignancies
May 29, 2024
RMAT designation granted for both TSC-100 and TSC-101 for the treatment of patients with AML, ALL, and MDS undergoing allogeneic HCT with reduced intensity conditioning
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TCRX Stock Earnings: TScan Therapeutics Misses EPS, Misses Revenue for Q1 2024
↗
May 13, 2024
TCRX stock results show that TScan Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
Via
InvestorPlace
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating TCR-T Therapy for the Treatment of Solid Tumors
May 09, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
TScan Therapeutics Announces Upcoming Presentations at the 2024 American Society of Clinical Oncology Annual Meeting
April 24, 2024
From
TScan Therapeutics, Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
